Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    21982118 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)
Condition: Hormone Refractory Prostate Cancer
Interventions: Drug: AT-101, prednisone and docetaxel;   Drug: placebo, prednisone and docetaxel

Indicates status has not been verified in more than two years